Skip to main content
. 2016 Jan;18(1):131–143. doi: 10.1016/j.jmoldx.2015.08.004

Figure 4.

Figure 4

Validation of CN alterations in Adv-DTC. A: Representative Nanostring nCounter results for individuals 2380, 2474, and 2299. Red dashed line represents CN = 2 (normal) values in Illumina SNP-CGH, red faded box represents Nanostring CN = 1.5–2.5 normal range. B: Overall validation of CNAs detected in six individuals with the use of Nanostring nCounter assay (Loss: true = CN ≤ 1.4, Ambiguous = CN1.5–1.6, false = CN ≥ 1.7; Gain: true = CN ≥ 2.6, ambiguous = CN2.4–2.5, false = CN ≤ 2.3). C: Quantitation of AR amplification in 2474; other DTC and CD45+ samples do not have AR amplification. D: Quantitation of PTEN loss in 2299 and 2439; other DTC and CD45+ samples have normal PTEN CN. Dashed gray lines in B and C represent mean CN of nonaberrant samples. Adv, advanced; CGH, comparative genome hybridization; CN, copy number; CNA, copy number aberration; DTC, disseminated tumor cell; SNP, single-nuclear polymorphism.